Oops. Sounds as if some people have got their fingers burnt and aren't happy. It seems to have been completely back-to-front: make a drug then find a disease for it. But if you have to work that way, why start with illnesses nobody knows anything about? You'd think they'd look at those where there's some understanding of what goes awry, so they at least have a chance of matching it to the theoretical mode of action.
Seems like those are the only ones left. They have already claimed that Ampligen cures AIDS, cancers etc in the past and have always failed to show any efficacy. The everlasting miracle drug that's still waiting to perform its first miracle.
This sounds like what investment people call "activist shareholders". When a company is doing poorly, sometimes new or existing investors will campaign for replacing the leadership and reform. And indeed, AIM Immunotech is following the typical path of biotech startups. Investing in biotech is somewhat like playing the lottery. Most of them fail but the ones that succeed are massively profitable. AIM initially had an interesting product and raised a bunch of money, but then it failed in trials, and now the company is nearly worthless. I did come poking around AIM's financial reports a few years ago. They had negligible revenue (in the of thousands), R&D expenses in the millions, and somewhere around $50M cash saved up. Unless they have unexpected success in a trial, they will probably close up shop once their savings run out, because who would invest in or lend money to a company that's failed to get any real revenue for 20 years? Edit: Perusing some materials by the Keller group trying to overturn the board, they have very little cash and are getting money by issuing more stock. This dilutes existing shareholders' portions but they have no other options.
I have never seen anything immunologically credible about Ampligen. It has always looked like something based on garbled pseudoscience. I never cease to be amazed at the way people will treat medical research just as a casino.
Kellner Group denounces false rumors about AIM short selling and demands immediate accountability from incumbent board. https://www.globenewswire.com/news-...iate-Accountability-from-Incumbent-Board.html
